December 10, 2024 03:44 PM EST
R&D

Ear­ly da­ta on BTK de­graders sug­gest promise of next-gen ap­proach

Lei Lei Wu

News Reporter

Nicole DeFeudis

Editor

SAN DIEGO — Drug de­vel­op­ers are mak­ing a new gen­er­a­tion of treat­ments for blood can­cers that arise from ab­nor­mal B cells by tak­ing ad­van­tage of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

US with­draw­al from WHO could jeop­ar­dize in­for­ma­tion shar­ing

Sanofi says no sup­ply in­ter­rup­tions af­ter land­ing FDA warn­ing let­ter for US site

Re­newed mifepri­s­tone fight will be ear­ly test of Trump’s abor­tion stance in his sec­ond term

Sion­na and Odyssey end JPM week with IPO fil­ings

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times